DOCSLIB.ORG

In Acute Myocardial Infarction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Acute Myocardial Infarction PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/145606 Please be advised that this information was generated on 2021-10-09 and may be subject to change. Fibrinolysis with recombinant single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction. Kringle ^т&^ Ж Ж J3ß®e&<äx&g$& ШШЕЖ J&&. •J>\c~i wwvaS-aW Proteinase Rolf Michels о* ел О ^η> δο, er S- ел то S β" eη r о В* о η Я то *1 о < и η η S« Β ο ¡а О ·% WW« С » er 't ο Ρ 3 η ё «-f α то о s: CL в ο Ρ re eu 5Г о tu Cu и' о W рг g* СЛ м ft e¡. η Ρ Ρ о er α Κ э г» -s л g то CA 3 Τ) Fibrinolysis with recombinant single-chain urokinase- type plasminogen activator (saruplase) in acute myocardial infarction Fibrinolyse met recombinant single-chain urokinase-type plasminogen activator (saruplase) bij het acute myocardinfarct Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Nijmegen op gezag van de Rector magnificus Prof. Dr T.J.M, van Els en volgens het besluit van het College van Decanen. De openbare verdediging zal plaats vinden op vrijdag 18 juni 1999 om 11.00 uur door Herman Rudolf Michels Geboren te Paramaribo in 1945. Promotor: Prof. Dr. F.W. Α. Verheugt Co-promotor: Prof. Dr. F.W.H.M. Bär (Universiteit Maasstricht) Referent: Prof. Dr. D. Collen (Katholieke Universiteit Leuven) Manuscriptcommissie: Prof. Dr. P. Smits (voorzitter) Prof. Dr. J.H.J. Ruijs Prof. Dr. T. de Witte Publication of this thesis was financially supported by the Cardiac Therapy Research Institute Eindhoven, 'CATHREINE'. 1/w»i: WcáeUe. ÇeAtute-TïùvUe. Çac<$ueU*te e*t л*иёае Some returns on investment are impossible to measure (N. Rockefeller) Contents Chapter 1 11 General introduction Chapter 2 15 Saruplase in acute myocardial infarction. Frits W. Bär, Frank Vermeer, Rolf Michels, Jean Boland, Jürgen Meyer, Gwyn Hopkins, Hannes Barth, Wolfgang A. Giinzler. J Thromb Thrombol 1995; 2:195-204. Reprinted with permission from the Journal of Thrombosis and Thrombolysis. ©Kluwer Academic Publishers, Boston. Chapter 3 35 A double-blind multicenter comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: report of the SUTAMI study group. Rolf Michels, Hans Hoffmann, Jürgen Windeler, Hannes Barth, and Gwyn Hopkins on behalf of the SUTAMI investigators. J Thromb Thrombol 1995; 2: 117-124. Reprinted with permission from the Journal of Thrombosis and Thrombolysis. ©Kluwer Academic Publishers, Boston. Chapter 4 55 Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator). H.R. Michels, J.J.M.L. Hoffmann, J. Windeler, G.R. Hopkins. Blood Coag and Fibrinolysis 1996; 7: 766-771. Reprinted with permission from Blood Coagulation & Fibrinolysis. ©1996, Rapid Science Publishers Chapter 5 69 Plasma markers of thrombin activity during coronary thrombolytic therapy with saruplase or urokinase: no prediction of reinfarction. J.J.M.L. Hoffmann, H.R. Michels, J. Windeler, W.A. Günzler. Fibrinolysis 1993; 7: 330-334. Reprinted with permission from Fibrinolysis. © Longman Group, UK Ltd. Chapter 6 83 Comparison of saruplase and alteplase in acute myocardial infarction. Frits W. Bär, Jürgen Meyer, Frank Vermeer, Rolf Michels, Bernard Charbonnier, Klaus Haerten, Martin Spiecker, Carlos Macaya, Michel Hanssen, Magda Heras, Jean P. Boland, Marie-Claude Morice, Francis G. Dunn, Rainer Uebis, Christian Hamm, Oded Ayzenberg, Gerhard Strupp, Adrie Withagen, Werner Klein, Jürgen Windeler, Gwyn Hopkins, Hannes Barth, Michael von Fisenne, for the SESAM study group. Am J Cardiol 1997; 79: 727-732. Reprinted with permission from the American Journal of Cardiology. © 1997 by Excerpta Medica, Inc. Chapter 7 99 Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. Ulrich Tebbe, Rolf Michels, Jennifer Adgey, Jean Boland, Avi Caspi, Bernard Charbonnier, Jürgen Windeler, Hannes Barth, Robert Groves, Gwyn R. Hopkins, Wiliam Fennell, Amadeo Betriu, Mikhial Ruda, Johannes Mlzoch, for the COMPASS trial of saruplase and streptokinase (COMPASS) investigators. J Am Coll Cardiol 1998; 31: 487-493. Reprinted with permission from the American Society of Cardiology. © 1998 by the American College of Cardiology. Chapter 8 119 Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction. Comparison of infusion, single bolus and split-bolus administration. H.R. Michels, J.J.M.L. Hoffmann, F.W. H. M. Bär. Submitted for publication.. Chapter 9. Summary and conclusions 137 Fibrinolysis with recombinant single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction. Summary of the results of clinical trials. H.R. Michels, F.W.H.M. Bär, F.W.A. Verheugt. Submitted for publication. Chapter 10 159 Samenvatting en conclusies. Dankbetuiging 163 Curriculum vitae 165 10 INTRODUCTION Chapter 1 General introduction Rapid and sustained coronary reperfusion and the prevention of (sub)acute reocclusion, bleeding complications and allergic reactions are the main objectives of coronary thrombolysis for acute myocardial infarction.With currently used intravenous thrombolytic agents the time to reperfusion is usually greater than 45 min and (sub)acute reocclusion is not infrequent. Current thrombolytics result in, at best, a maximum patency of 75% at 90 min after the start of infusion. The most commonly used agent, streptokinase reaches this plateau only hours later. Streptokinase is a nonphysiological, non-fibrin-selective fibrinolytic agent. The physiological fibrin-selective recombinant tissue-type plasminogen activator (rt-PA) has shown a difference to streptokinase in terms of efficacy of early reperfusion. The risk of reocclusion probably varies with different thrombolytic agents, and may be related to the extent of systemic lysis (i.e. plasmin generation), fibrinogen depletion, increase of (fibrinogen) degradation products, alteration of platelet activity and blood viscosity and the severity and geometry of residual stenosis. Bleeding complications occur in approximately 10-15% of patients. There is a trend towards more hemorrhagic strokes with the more potent fibrin-selective agents. This trend may partially counteract the benefit of more rapid reperfusion. Nonphysiological fibrinolytic agents consist of proteins which are foreign to the human body and may generate antibodies and cause allergic reactions. Shortly after streptokinase administration the anti-streptokinase titer rises up to 100 times the baseline value and remains high for over 6 months. Since antibodies may affect thrombolytic efficacy, streptokinase should not be re-administered during this time. "Time is myocardium": storage, preparation and administration of medication should be as simple as possible (preferably as a bolus). Better drugs are generally more expensive, however, greater efficacy should also be cost-effective. In summary, a fibrinolytic agent should ideally show very early maximum reperfusion, little reocclusion, no excess of bleeding, and no antibody formation. Moreover preparation and administration should be simple, and the drug should be inexpensive. None of the currently available agents fulfills all of these criteria, and whilst rt-PA so far appears the most satisfactory it is not exactly inexpensive, and is not recommended to be 11 CHAPTER 1 administered as a bolus. The focus is therefore on effective, physiological, fibrin-selective, not-too-expensive newcomers in the field of fibrinolytic therapy, that possess none of the disadvantages of the currently commercially available fibrinolytic agents. Saruplase is examined in the light of these criteria. A detailed evaluation of the newer mutants of wild- type t-PA, such as lanetoplase, reteplase, and TNK-t-PA, is beyond the scope of this review, the aim of which will be restricted to discussing recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in the context of fibrinolytic medications commercially available in Europe. Of the latter only streptokinase and rt- PA have gained widespread popularity in clinical practice. The human enzyme urokinase or two-chain urokinase-type plasminogen activator (tcu- PA), is an effective but expensive fibrinolytic agent that has been registered for acute myocardial infarction in some, but not all European countries. In this thesis the studies that compare saruplase (given as a bolus of 20 mg intravenously followed by an infusion of 60 mg over 1 hour) with streptokinase, urokinase and rt-PA will be presented and discussed. In addition the pharmacokinetics and hemostatic effects of single bolus and split-bolus administration of saruplase will be presented and discussed. No comparisons of saruplase with anistreplase, currently the only fibrinolytic agent available for a single bolus administration, or with reteplase, recently registered for double bolus administration, are available. Anistreplase, or anisoylated plasminogen-streptokinase-activator complex (APSAC), may have some benefits over streptokinase, but it not only has all the shortcomings of that agent, and its high price has generally operated against its widespread use. The efficacy and safety of reteplase and rt-PA are quite comparable. APSAC and the newer
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Syddansk Universitet Assessing Safety of Thrombolytic Therapy Kluft, Cornelis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Southern Denmark Research Output Syddansk Universitet Assessing safety of thrombolytic therapy Kluft, Cornelis; Sidelmann, Johannes Jakobsen; Gram, Jørgen Brodersen Published in: Seminars in Thrombosis and Hemostasis DOI: 10.1055/s-0036-1584130 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license Unspecified Citation for pulished version (APA): Kluft, C., Sidelmann, J. J., & Gram, J. B. (2017). Assessing safety of thrombolytic therapy. Seminars in Thrombosis and Hemostasis, 43(3), 300-310. DOI: 10.1055/s-0036-1584130 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 12. aug.. 2017 300 Assessing Safety of Thrombolytic Therapy Cornelis Kluft, PhD1,2 Johannes J. Sidelmann, PhD2 Jørgen B. Gram, DMSc2,3 1 Good Biomarker Sciences, Leiden, The Netherlands Address for correspondence Cornelis Kluft, PhD, Good Biomarker 2 Unit for Thrombosis Research, Department of Public Health, Sciences, Zernikedreef 8, 2333 CL Leiden, The Netherlands University of Southern Denmark, Esbjerg, Denmark (e-mail: [email protected]).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Randomized, Double-Blind Study Comparing Saruplase with Streptokinase Therapy in Acute Myocardial Infarction: the COMPASS Equivalence Trial
    JACC Vol. 31, No. 3 487 March 1, 1998:487–93 CLINICAL STUDIES MYOCARDIAL INFARCTION Randomized, Double-Blind Study Comparing Saruplase With Streptokinase Therapy in Acute Myocardial Infarction: The COMPASS Equivalence Trial ULRICH TEBBE, MD, ROLF MICHELS, MD,* JENNIFER ADGEY, MD, FRCP,† JEAN BOLAND, MD,‡ AVI CASPI, MD,§ BERNARD CHARBONNIER, MD,\ JU¨ RGEN WINDELER, MD,¶ HANNES BARTH, MD,# ROBERT GROVES, PHD,# GWYN R. HOPKINS, BSC, MRCP, MFPM,# WILLIAM FENNELL, MD, FRCPI,** AMADEO BETRIU, MD,†† MIKHAIL RUDA, MD,‡‡ JOHANNES MLCZOCH, MD,§§ FOR THE COMPARISON TRIAL OF SARUPLASE AND STREPTOKINASE (COMASS) INVESTIGATORS\\ Lippe-Detmold, Bochum and Aachen, Germany; Eindhoven, The Netherlands; Belfast, Northern Ireland, United Kingdom; Lie`ge, Belgium; Rehovot, Israel; Tours, France; Cork, Ireland; Barcelona, Spain; Moscow, Russian Federation; and Vienna, Austria Objectives. This study sought to demonstrate the equivalence of Results. Death of any cause up to 30 days after randomization saruplase and streptokinase in terms of 30-day mortality. occurred in 88 (5.7%) of 1,542 patients randomized to receive Background. The use of thrombolytic agents in the treatment of saruplase and 104 (6.7%) of 1,547 patients randomized to receive acute myocardial infarction is well established and has been streptokinase (odds ratio 0.84, p < 0.01 for equivalence). Hemor- shown to substantially reduce post-myocardial infarction mortal- rhagic strokes occurred more often in patients receiving saruplase ity. (0.9% vs. 0.3%), whereas thromboembolic strokes were more Methods. Three thousand eighty-nine patients with symptoms prevalent in the streptokinase-treated patients (0.5% vs. 1.0%). compatible with those of acute myocardial infarction for <6 h The rate of bleeding was similar in the two treatment groups entered the study at a total of 104 centers and were randomized to (10.4% vs.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]